Addressing the Public Health Effects of Opioid Medications

Hybrid Public Meeting
September 9, 2026 | 12:30-4:30pm (eastern)

The Foundation, in collaboration with the FDA, will convene a hybrid meeting to hear public comments on perspectives regarding the use of opioid medications for the management of pain and addiction. The meeting will also feature a panel discussion with federal partners to discuss efforts to improve the management of pain and addiction. 

While the Thursday, August 27 deadline to request to present public comment at the meeting has passed, you are invited to submit written public comments until September 23. 

We invite patients, family members/caregivers, healthcare providers, drug developers, and others to provide public comment on the following topics. To submit written public comments, click here.

  1. Scientific evidence regarding conditions of use, safety concerns, or benefit-risk assessment (including consideration of the public health effects) of opioid medications
  2. Input on FDA’s regulation of opioid medications
  3. Additional actions that could be considered to address the public health effects of opioid medications

This is a hybrid event with options to attend virtually or in person at 10903 New Hampshire Ave., Bldg. 31 Conference Center, Great Room, Silver Spring, MD.

Please use the buttons below to register to attend.

If you experience registration issues, please contact admin@reaganudall.org.

Register to Attend In-Person
Register to Attend Virtually

Agenda

 

This meeting is one of several engagement activities being conducted in collaboration with the FDA in partial fulfillment of Section 112 of the SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483), “Assessment of Opioid Drugs and Actions.”

This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an award of $117,983 in federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit FDA.gov.